{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:09:21Z","timestamp":1780445361903,"version":"3.54.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"abstract":"<jats:p>Patients undergoing transcatheter aortic valve replacement (TAVR) have a high comorbid burden. Our objective was to assess the association between the age-adjusted Charlson comorbidity index (Age-CCI) and mortality and readmission rates within 1-year post-TAVR. Data were extracted from the Medical Information Mart for Intensive Care IV database (MIMIC-IV version 2.0). The primary endpoint was a composite outcome of all-cause mortality or readmission within 1-year after TAVR. To examine the associations of Age-CCI with outcomes, we used multivariable Cox proportional hazards regression, restricted cubic spline (RCS), and Kaplan\u2013Meier curves. A total of 785 patients (52.9% male) with a median age of 84.0 years were assessed. More than half of our patients had an Age-CCI \u2265 7. After adjustment for potential confounders, we found that a 1 unit increase in Age-CCI was associated with a 10% increase in mortality and readmission rates after TAVR (HR = 1.10, 95% CI: 1.04\u20131.17, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). High Age-CCI (Age-CCI \u2265 7) compared with the low Age-CCI (Age-CCI &lt; 7) showed a 36% increase of mortality and readmission rates (HR = 1.36, 95% CI: 1.07\u20131.73, <jats:italic toggle=\"yes\">P =<\/jats:italic> .013). The RCS curve analysis showed a continuous linear relationship between Age-CCI and the composite outcome risk (<jats:italic toggle=\"yes\">P<\/jats:italic> for non-linearity = .671). The Kaplan\u2013Meier survival analysis showed that patients with Age-CCI \u2265 7 had a poorer prognosis than those with Age-CCI &lt; 7 (log-rank <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). Subgroup analyses showed the results remained stable. Age-CCI is independently associated with all-cause mortality and readmission in patients treated with TAVR, which may help clinicians risk-stratify patients and offer an opportunity to improve patient outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000036283","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:04:18Z","timestamp":1701716658000},"page":"e36283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Association of age-adjusted Charlson comorbidity index with adverse outcomes in patients undergoing transcatheter aortic valve replacement: A retrospective cohort study"],"prefix":"10.1097","volume":"102","author":[{"given":"Hua","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"},{"name":"Department of Cardiology, Handan First Hospital, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"},{"name":"Department of Cardiology, Handan First Hospital, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanli","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan First Hospital, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan First Hospital, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Handan First Hospital, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-4074","authenticated-orcid":false,"given":"Bingyan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250524","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250524","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","article-title":"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.","volume":"376","author":"Reardon","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250524","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"key":"R4-20250524","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jacc.2021.02.032","article-title":"Transcatheter versus surgical aortic valve replacement in patients with rheumatic aortic stenosis.","volume":"77","author":"Mentias","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250524","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/icvts\/ivu155","article-title":"Transcatheter aortic valve implantation of a second-generation valve for pure aortic regurgitation: procedural outcome, haemodynamic data and follow-up.","volume":"19","author":"Schlingloff","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R6-20250524","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.2015.1474","article-title":"Clinical outcomes at 1 year following transcatheter aortic valve replacement.","volume":"313","author":"Holmes","year":"2015","journal-title":"JAMA"},{"key":"R7-20250524","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2018.07.073","article-title":"Hospital readmission following transcatheter aortic valve implantation in the real world.","volume":"269","author":"Arai","year":"2018","journal-title":"Int J Cardiol"},{"key":"R8-20250524","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cjca.2018.11.016","article-title":"The relationship between heart-failure hospitalization and mortality in patients receiving transcatheter aortic valve replacement.","volume":"35","author":"Nazzari","year":"2019","journal-title":"Can J Cardiol"},{"key":"R9-20250524","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jcin.2017.09.010","article-title":"Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement.","volume":"10","author":"Durand","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R10-20250524","doi-asserted-by":"crossref","first-page":"e008959","DOI":"10.1161\/CIRCINTERVENTIONS.120.008959","article-title":"Determinants and impact of heart failure readmission following transcatheter aortic valve replacement.","volume":"13","author":"Auffret","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"R11-20250524","doi-asserted-by":"crossref","first-page":"e004472","DOI":"10.1161\/CIRCINTERVENTIONS.116.004472","article-title":"Thirty-day readmissions after transcatheter aortic valve replacement in the united states: insights from the nationwide readmissions database.","volume":"10","author":"Kolte","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"R12-20250524","doi-asserted-by":"crossref","first-page":"e002096","DOI":"10.1161\/JAHA.115.002096","article-title":"Causes of death following transcatheter aortic valve replacement: a systematic review and meta-analysis.","volume":"4","author":"Xiong","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R13-20250524","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index.","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"R14-20250524","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R15-20250524","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/heartjnl-2014-306694","article-title":"Long-term outcome after transcatheter aortic valve implantation.","volume":"101","author":"Bouleti","year":"2015","journal-title":"Heart"},{"key":"R16-20250524","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ehjqcco\/qcw001","article-title":"Functional performance and quality of life in high-risk comorbid patients undergoing transcatheter aortic valve implantation for symptomatic aortic valve stenosis.","volume":"2","author":"Hiltrop","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R17-20250524","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.hlc.2018.11.006","article-title":"The influence of the Charlson comorbidity index on procedural characteristics, VARC-2 endpoints and 30-day mortality among patients who undergo transcatheter aortic valve implantation.","volume":"28","author":"George","year":"2019","journal-title":"Heart Lung Circ"},{"key":"R19-20250524","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1136\/heartjnl-2018-313356","article-title":"Association of comorbid burden with clinical outcomes after transcatheter aortic valve implantation.","volume":"104","author":"Bagur","year":"2018","journal-title":"Heart"},{"key":"R20-20250524","doi-asserted-by":"crossref","first-page":"e018978","DOI":"10.1161\/JAHA.120.018978","article-title":"Comorbidity burden and adverse outcomes after transcatheter aortic valve replacement.","volume":"10","author":"Feldman","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R21-20250524","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cjca.2020.03.015","article-title":"Acute kidney injury following aortic valve replacement in patients without chronic kidney disease.","volume":"37","author":"Moriyama","year":"2021","journal-title":"Can J Cardiol"},{"key":"R22-20250524","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ahj.2011.11.013","article-title":"Survival and predictive factors of mortality after 30 days in patients treated with percutaneous implantation of the CoreValve aortic prosthesis.","volume":"163","author":"Mu\u00f1oz-Garc\u00eda","year":"2012","journal-title":"Am Heart J"},{"key":"R23-20250524","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ccd.25708","article-title":"Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation.","volume":"85","author":"Barbash","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"R24-20250524","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jacc.2013.09.024","article-title":"Outcomes of patients with chronic lung disease and severe aortic stenosis treated with transcatheter versus surgical aortic valve replacement or standard therapy: insights from the PARTNER trial (placement of AoRTic TraNscathetER Valve).","volume":"63","author":"Dvir","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R25-20250524","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.jacc.2019.03.496","article-title":"Transcatheter aortic valve replacement in patients with end-stage renal disease.","volume":"73","author":"Szerlip","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:01:29Z","timestamp":1748109689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":24,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036283","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}